We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.14 | -0.13% | 106.15 | 106.76 | 105.15 | 106.71 | 3,735,828 | 01:00:00 |
From May 2021 to May 2024
By Matt Grossman
Abbott Laboratories on Wednesday posted greater third-quarter sales and earnings year over year, with Covid-19 testing revenue giving the company's diagnostics business a lift.
The Abbott Park, Ill.-based medical-products maker posted earnings of $1.17 a share, up from 69 cents a share 12 months ago. Net earnings rose to $2.1 billion from $1.23 billion in the prior-year period.
Stripping out one-time items, Abbott's adjusted earnings were $1.40 a share. According to FactSet's survey, analysts were forecasting adjusted earnings of 94 cents a share.
Sales rose to $10.93 billion, from $8.85 billion a year ago. Analysts had been anticipating sales of $9.56 billion.
Sales grew across the company's divisions. Nutrition sales were up 9.6%, while medical-device sales climbed 15%. Diagnostics sales rose 48%, boosted by Covid-19 testing.
Abbott's global Covid-19 testing sales were $1.9 billion in the quarter.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 20, 2021 07:57 ET (11:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
